Acadia Pharmaceuticals Inc., of San Diego, priced a $100 million public offering of 8 million shares of common stock at $12.50 apiece, a 3.5 percent discount to Tuesday's closing price...Proceeds will be used to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin, as well as activities for other product candidates and for general corporate purposes...Receptos will use the proceeds to support clinical work in multiple sclerosis, inflammatory bowel disease

Discovery Laboratories Inc., of Warrington, Pa., said it priced a $14.25 million public offering of 9.5 million shares of common stock at $1.50, an 8.5 percent discount to Thursday's closing price...Net proceeds are expected to total about $16.1 million and will be used for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for R&D expenses such as clinical trials of its OMS103HP, PDE10, MASP-2 and PDE7

Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 months...The scope of the public offering – on the heels of five partnerships generating more than $125 million in up-front payments in the last 16 months – is designed to plug those development gaps

Receptos Inc., of San Diego, priced its initial public offering (IPO) of 5.2 million shares of common stock at $14 per share, for a total raise of $72.8 million...The funds will support clinical work in multiple sclerosis (MS), inflammatory bowel disease (IBD) and allergic/immune-mediated disorders. (See BioWorld Today, April 8, 2013.) The pricing hits pretty close to the $86.3 million target set when the company filed for its offering only a month ago

The drug has gone through 12 clinical trials in more than 1,400 subjects already, showing that it knocks down serum bile acid levels safely...Lumena plans to complete the Phase I clinical program of LUM002 in healthy volunteers later this year...Idera Pharmaceuticals Inc., of Cambridge, Mass., closed its previously announced $16.5 million underwritten public offering of 17.5 million shares of common stock and related warrants to purchase up to 17.5 million more shares of common stock at an exercise

spun out in 2011, and Flexion Therapeutics Inc., of Woburn, Mass., founded by veterans of Eli Lilly and Co.'s Chorus division to advance abandoned early clinical programs through proof of concept. (See BioWorld Today, Feb. 1, 2010, and July 28, 2011.) The $15 million investment in Tacurion will support a Phase II proof-of-concept trial for the drug that should take 18 months to two years to complete...Portola Pharmaceuticals Inc., of South San Francisco, set the price range for its proposed initial

shored up its balance sheet in a $36 million private offering to advance pipeline work, including planned clinical trials of ARC-520, an RNAi-based drug in chronic HBV infection...Arrowhead ended 2012 with about $2.9 million in cash, with another $3.5 million raised via a public offering in January...Shares of Supernus (NASDAQ:SUPN) lost 3 cents Monday to close at $5.12.

GW Pharmaceuticals plc, of Porton Down, UK, said it priced its initial public offering (IPO) of 3.5 millionAmerican Depository Shares (ADS) on the Nasdaq Global Market at $8.90 per ADS...The exercise of the overallotment option brings the total gross proceeds from the offering to $10.75 million. (See BioWorld Today, May 1, 2013.)

The possibility of an initial public offering (IPO) – noted in December, when Regado Biosciences Inc...NeoStem Inc., of New York, priced an underwritten public offering of 20 million shares of common stock at 50 cents apiece, seeking to generate $10 million

Anacor Pharmaceuticals Inc., of Palo Alto, Calif., said it priced a public offering of about 3...The funding allowed ReXceptor to enter a formal partnership with C2N Diagnostics, which will assist the company with the initiation and coordination of the clinical trial of an AD program licensed from Case Western's Technology Transfer Office and based on discoveries that bexarotene, a medication sold at Targretin for cutaneous T-cell lymphomas, reversed AD symptoms in mice within 72 hours of a single

AG014 comprises oral delivery of an anti-TNF antibody with proven clinical efficacy in IBD, resulting in local efficacy and an improved safety profile over systemic drugs...ERYtech Pharma SA, of Lyon, France, has had its prospectus accepted for a proposed initial public offering on the NYSE Euronext exchange in Paris

ChemoCentryx Inc., of Mountain View, Calif., commenced its underwritten public offering of $60 million in common stock...Omthera Pharmaceuticals Inc., of Princeton, N.J., said it closed its initial public offering of 8 million shares priced at $8 apiece for gross proceeds of $64 million

Coronado plans to use the proceeds to fund R&D, clinical trials and manufacture of supply as well as other corporate purposes...Omthera Pharmaceuticals Inc., of Princeton, N.J., priced its initial public offering (IPO) at $8 apiece, below the company's target range of $12 to $14

biotech to file for an initial public offering (IPO) this year, taking advantage of the emerging growth company provision in the Jumpstart Our Business Start-ups Act and aiming to raise as much as $86.3 million to support clinical work in multiple sclerosis, inflammatory bowel disease (IBD) and allergic/immune-mediate disorders

Net proceeds totaled $12 million and will be used to fund R&D and clinical trials, acquisition of intellectual property and other purposes...The funds will be used to advance Theraclone's clinical programs and support its I-STAR technology platform.

priced a $56 million initial public offering (IPO) and received a warm welcome from Wall Street, as its newly listed shares shot up 22.7 percent on its first day of trading...Net proceeds are expected to support clinical trial costs and acquisition of manufacturing equipment, leasehold improvements and general corporate purposes

The German Federal State of Saxony and the European Union funded the grant, which supplements a grant awarded by the SAB in August 2011 for the CANVAS clinical trial...Net proceeds of about $12 million will be used to support R&D, acquisition of intellectual property related to complementary drug therapies, clinical trials and other expenses...The first tranche of the Series B closed in June 2012 for $8.6 million.

Cerus Corp., of Concord, Calif., priced a public offering of about 8.3 million shares of its common stock, offered at a price to the public of $4.20 per share...Cerus anticipates using the net proceeds for clinical development and other R&D activities related to the Intercept Blood System, preparatory activities for the potential commercialization of the system in the U.S

upsized a public offering of about 2.9 million shares of common stock, priced at $20.75, seeking to raise $59.7 million...priced a public offering, seeking to raise $207.2 million. (See story in this issue.) Since March 1, Achillion Pharmaceuticals Inc., Enanta Pharmaceuticals Inc